Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Guardant Health. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Guardant Health's earnings available for a low price, and how does
this compare to other companies in the same industry?
Guardant Health's earnings are expected to grow significantly at over 20% yearly.
Guardant Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Guardant Health's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Helmy Eltoukhy, PhD is the Co-founder of Guardant Health Inc. and serves as its Chief Executive Officer and Director. Dr. Eltoukhy is a serial entrepreneur and pioneer in the biotech industry. He joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome, Inc. to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As founding Chief Executive Officer, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Dr. Eltoukhy was Sr. Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. He received his PhD, MS and BS degrees in electrical engineering from Stanford University.
Helmy's compensation has been consistent with company performance over the past year, both up more than 20%.
Helmy's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Guardant Health management team is over 5 years, this suggests they are a seasoned and experienced team.
Chief Medical Officer
Chief LUNAR Officer & GM
Chief Financial Officer
Chief Legal Officer
Chief User Engagement Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Guardant Health board of directors is less than 3 years, this suggests a new board.
Do Insiders Own Lots Of Shares In Guardant Health, Inc. (NASDAQ:GH)?
Guardant Health has a market capitalization of US$5.7b, so it's too big to fly under the radar. … Our analysis of the ownership of the company, below, shows that. … View our latest analysis for Guardant Health
Guardant Health, Inc. (NASDAQ:GH): Financial Strength Analysis
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Guardant Health, Inc. … Don’t forget that this is a general and concentrated examination of Guardant Health's financial health, so you should conduct further analysis. … View our latest analysis for Guardant Health
What Kind Of Shareholder Appears On The Guardant Health, Inc.'s (NASDAQ:GH) Shareholder Register?
A look at the shareholders of Guardant Health, Inc. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We'd expect to see both institutions and retail investors owning a portion of the company.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.